Gastrointestinal Therapeutics and Diagnostics Market

Gastrointestinal disorders are related to digestive system and generally affect the colon, small & large intestine and rectum. The disorders include constipation, peptic ulcer diseases and irritable bowel syndrome. The major reason and cause of GI disorders are stress, intake of medicines such as iron pills and anti-depressants and unhealthy eating habits. Symptoms of the gastrointestinal infections include pain, bloating, diarrhea, nausea and vomiting. The major drugs that dominate the gastrointestinal diagnostics and therapeutics market are aciphex, afinitor, akynzeo, dificid and Prilosec.

Gastrointestinal Therapeutics and Diagnostics Market contains market size and forecasts of Gastrointestinal Therapeutics and Diagnostics in Global, including the following market information:

• Global Gastrointestinal Therapeutics and Diagnostics Market Revenue, 2017-2022, 2023-2028, ($ millions)
• Global top five companies in 2021 (%)

The global Gastrointestinal Therapeutics and Diagnostics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Diagnostics Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Gastrointestinal Therapeutics and Diagnostics include Abbott Laboratories, AstraZeneca, Eisai, Johnson & Johnson, Salix Pharmaceuticals and Takeda Pharmaceutical Company, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Gastrointestinal Therapeutics and Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Gastrointestinal Therapeutics and Diagnostics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Gastrointestinal Therapeutics and Diagnostics Market Segment Percentages, by Type, 2021 (%)

• Diagnostics
• Therapeutics

Global Gastrointestinal Therapeutics and Diagnostics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Gastrointestinal Therapeutics and Diagnostics Market Segment Percentages, by Application, 2021 (%)

• Gastroenteritis
• GI Bleeding
• Irritable Bowel Syndrome
• Peptic Ulcer Disease (PUD)
• Others

Global Gastrointestinal Therapeutics and Diagnostics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Gastrointestinal Therapeutics and Diagnostics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Gastrointestinal Therapeutics and Diagnostics revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Gastrointestinal Therapeutics and Diagnostics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Abbott Laboratories
• AstraZeneca
• Eisai
• Johnson & Johnson
• Salix Pharmaceuticals
• Takeda Pharmaceutical Company